Last reviewed · How we verify
Diabetes mellitus type 2 at increased risk of cardiovascular disease — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Inpefa | SOTAGLIFLOZIN | Lexicon Pharms Inc | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | Sodium/glucose cotransporter 2 | 2023-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Lexicon Pharms Inc · 1 drug in Diabetes mellitus type 2 at increased risk of cardiovascular disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Diabetes mellitus type 2 at increased risk of cardiovascular disease:
- Diabetes mellitus type 2 at increased risk of cardiovascular disease treatment updates — RSS
- Diabetes mellitus type 2 at increased risk of cardiovascular disease treatment updates — Atom
- Diabetes mellitus type 2 at increased risk of cardiovascular disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Diabetes mellitus type 2 at increased risk of cardiovascular disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diabetes-mellitus-type-2-at-increased-risk-of-cardiovascular-disease. Accessed 2026-06-10.
Related
- Diabetes mellitus type 2 at increased risk of cardiovascular disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing